A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2011
10/11/2011	US8034354 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
10/11/2011	US8034353 Peptide vaccine for inducing the production of anti-amyloid β-peptide antibody
10/11/2011	US8034352 Tetrameric cytokines with improved biological activity
10/11/2011	US8034351 Mucin fusion polypeptide vaccines, compositions and methods of use thereof
10/11/2011	US8034350 Methylated tat polypeptides and methods of use thereof
10/11/2011	US8034349 Peptides that mimic non-human cross-reactive protective epitopes of the group B meningococcal capsular polysaccharide
10/11/2011	US8034348 Prevention and treatment of amyloidogenic disease
10/11/2011	US8034347 Method for inhibiting apoptosis through the p75 neurotrophin receptor
10/11/2011	US8034346 Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
10/11/2011	US8034345 Anti-PCI antibody for regulating liver regeneration/repair
10/11/2011	US8034344 Anti-IL-6/IL-6R antibodies and methods of use thereof
10/11/2011	US8034343 Methods of treating inflammatory disorders of the lungs
10/11/2011	US8034342 for treating degenerative cartilaginous disorders and other inflammatory diseases; interleukin-17 receptor protein
10/11/2011	US8034341 Methods of inhibiting tumor growth using blocking antibodies to IL-23R
10/11/2011	US8034340 Method for treating an immune disorder by decreasing NIK-SIVA complex formation
10/11/2011	US8034339 administering an antibody that specifically binds to the amyloid deposit or a component thereof; can be a human, humanized, chimeric or nonhuman antibody and can be monoclonal or polyclonal; also a novel monoclonal antibody which specifically binds to an epitope within residues 13-28 of A beta
10/11/2011	US8034338 Immunogenic recombinant antibody
10/11/2011	US8034337 Interleukin-1α antibodies
10/11/2011	US8034336 Antibodies against a peptide epitope of apoliprotein B
10/11/2011	CA2504938C Compositions and methods for treating or preventing pneumococcal infection
10/11/2011	CA2476405C Compositions and methods for treatment of microbial infections
10/11/2011	CA2468258C Peptide agonists of prostate-specific antigen, and uses therefor
10/11/2011	CA2457027C Chitin microparticles and their medical uses
10/11/2011	CA2442993C Nucleic acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
10/11/2011	CA2424734C Nanoparticles comprising a metallic or semiconductor core which is covalently bound to a plurality of carbohydrate ligands
10/11/2011	CA2394862C Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder
10/11/2011	CA2378584C New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
10/11/2011	CA2362098C Human polyclonal antibodies from genetically engineered animals
10/11/2011	CA2341356C Poxvirus with targeted infection specificity
10/11/2011	CA2336743C Antigenic peptides derived from telomerase
10/11/2011	CA2248937C Peptide-based immunotherapeutic agent for treating allergic diseases
10/11/2011	CA2157932C Production of human papillomavirus capsid protein and virus-like particles
10/06/2011	WO2011123857A1 Generation of antibodies to an epitope of interest
10/06/2011	WO2011123826A2 Prevention and treatment of cast nephropathy
10/06/2011	WO2011123819A2 Epha3 antibodies for the treatment of multiple myeloma
10/06/2011	WO2011123813A2 Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
10/06/2011	WO2011123697A2 Histamine-releasing factor (hrf), hrf-receptor and methods of modulating inflammation
10/06/2011	WO2011123507A1 Humanized il-25 antibodies
10/06/2011	WO2011123495A1 Influenza virus vaccines and uses thereof
10/06/2011	WO2011123476A1 Methods and compositions for reducing parathyroid levels
10/06/2011	WO2011123452A1 Compositions and methods for prophylactic and therapeutic treatment of infection
10/06/2011	WO2011123428A1 Antibody-based depletion of antigen-presenting cells and dendritic cells
10/06/2011	WO2011123427A2 Treatment of cancer by inhibiting activity or expression of late sv-40 factor
10/06/2011	WO2011123396A1 Compositions and methods for the removal of biofilms
10/06/2011	WO2011123381A1 Antibodies against csf-1r
10/06/2011	WO2011123042A1 Vaccination procedure and products for use therein
10/06/2011	WO2011122843A2 Combined inactivated vaccine for prevention of streptococcicosis of fish and method for preparing same
10/06/2011	WO2011122634A1 Prognostic method for pulmonary adenocarcinoma, pulmonary adenocarcinoma detection kit, and pharmaceutical composition for treating pulmonary adenocarcinoma
10/06/2011	WO2011122611A1 Cancer vaccine
10/06/2011	WO2011121576A2 Immunogenic proteins and compositions
10/06/2011	WO2011121560A2 Stabilized antibody preparations and uses thereof
10/06/2011	WO2011121559A2 Stabilized antibody preparations and uses thereof
10/06/2011	WO2011121556A2 Monoclonal antibody directed against the p17 protein of hiv, capable of neutralising the binding of p17 to the p17 receptor (p17r)
10/06/2011	WO2011121306A1 Stabilisation of viral particles
10/06/2011	WO2011121305A2 Method for preserving alum adjuvants and alum-adjuvanted vaccines
10/06/2011	WO2011121301A1 Excipients for stabilising viral particles, polypeptides or biological material
10/06/2011	WO2011121110A1 CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
10/06/2011	WO2011121040A1 Humanized anti cxcr4 antibodies for the treatment of cancer
10/06/2011	WO2011120994A1 Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof
10/06/2011	WO2011120924A1 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
10/06/2011	WO2011120902A1 Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and tumor initiating cells
10/06/2011	WO2011120870A1 Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
10/06/2011	WO2011120135A1 Antibodies with enhanced or suppressed effector function
10/06/2011	WO2011120134A1 Antibodies with enhanced or suppressed effector function
10/06/2011	WO2011100620A3 Upar binding agents and methods of use thereof
10/06/2011	WO2011100566A3 Methods for identifying and isolating cells expressing a polypeptide
10/06/2011	WO2011100565A3 Multimeric proteins comprising immunoglobulin constant domains
10/06/2011	WO2011100233A3 Novel use of an il-12 receptor splice variant and molecular assay to quantify expression thereof
10/06/2011	WO2011098262A3 P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
10/06/2011	WO2011096894A3 Use of novel markers of pluripotent stem cells
10/06/2011	WO2011083090A3 Methods for treating breast cancer
10/06/2011	WO2011081294A3 Recombinant adenovirus having anti-angiogenesis activity
10/06/2011	WO2011077309A3 Vaccine compositions
10/06/2011	WO2011073215A3 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
10/06/2011	WO2011071574A3 Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
10/06/2011	WO2011060093A3 Compositions, methods and uses for stimulating immune responses
10/06/2011	WO2011059926A9 Methods and materials for treating renal cell carcinoma
10/06/2011	WO2011053763A3 Il-17a antagonists
10/06/2011	WO2011041350A9 Xenotropic mulv-related virus (xmrv) compositions and methods of use
10/06/2011	WO2011034583A3 Inhibition of endosomal toll-like receptor activation
10/06/2011	WO2010137017A3 Proteasome inhibitors and uses thereof
10/06/2011	WO2010089554A8 Grass peptides for vaccine
10/06/2011	US20110245470 Immunoglobulins
10/06/2011	US20110245146 Non-Viral Delivery of Compounds to Mitochondria
10/06/2011	US20110244574 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
10/06/2011	US20110244053 Use a goat serum for veterinary treatment
10/06/2011	US20110244044 Compound, medicament, vaccine composition and nanocapsules
10/06/2011	US20110244027 2'-Fluoro-6'-Methylene Carbocyclic Nucleosides and Methods of Treating Viral Infections
10/06/2011	US20110244025 Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
10/06/2011	US20110244021 Antimicrobial and immunostimulating composition
10/06/2011	US20110243994 Stabilized pharmaceutical composition, liquid preparation of stabilized pharmaceutical composition, film-form preparation, and method for producing film-form preparation
10/06/2011	US20110243993 Method for diagnosing and creating immunogenic tolerance in contact allergy and other epithelial immunotoxicological ailments
10/06/2011	US20110243992 Methods of enhancing the immunogenicity of mycobacteria and compositions for the treatment of cancer, tuberculosis, and fibrosing lung diseases
10/06/2011	US20110243991 Process for production of vaccines
10/06/2011	US20110243990 Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
10/06/2011	US20110243989 Idna vaccines and methods for using the same
10/06/2011	US20110243988 Methods and Compositions for Stabilization of a Virus Vaccine
10/06/2011	US20110243987 Influenza vaccine
10/06/2011	US20110243986 Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
10/06/2011	US20110243982 Chimeric MSP-Based Malaria Vaccine

1 ... 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 ... 1823